Webcast ImageWebcast
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call  (Live)
05/03/17 at 2:30 p.m. MT
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, May 3, 2017 2:30 p.m. MT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 0.78 (1.35%)
Intraday High$59.00
Intraday Low$56.60
Data as of 04/26/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
04/20/17Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 20, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis O... 
Printer Friendly Version 
03/28/17Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017
Abstracts provide new insights into rucaparib’s mechanism of action and function in multiple disease and therapy settings FDA approved Rubraca® (rucaparib) tablets in late 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer BOULDER, Colo.--(BUSINESS WIRE)--Mar. 28, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the Am... 
Printer Friendly Version 
03/12/17Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer
New rucaparib data presented today in two oral plenary sessions Data provide additional insights from ARIEL2 Phase 2 study of rucaparib in advanced ovarian cancer FDA approved Rubraca® (rucaparib) tablets in December 2016 as monotherapy treatment for women with BRCA-mutated advanced ovarian cancer based on data from Study 10 and ARIEL2 BOULDER, Colo.--(BUSINESS WIRE)--Mar. 12, 2017-- Clovis Onc... 
Printer Friendly Version 
Upcoming EventsMore >>
2:30 p.m. MT
Q1 2017 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.